Clinical study of trastuzumab combined with chemotherapy in the treatment of HER2-positive breast cancer
Abstract
Objective: To evaluate the efficacy of trastuzumab combined with chemotherapy in patients with human epidermal factor receptor 2 (HER2) positive breast cancer. Methods: A total of 88 patients with HER2 positive breast cancer treated in our hospital from 2023 to January 2024 were selected. They were divided into two groups according to the random number table method: the control group44 cases, treated with chemotherapy) and the observation group (44 cases, treated with trastuzumab combined with chemotherapy). The efficacy, incidence adverse reactions, recurrence rate, metastasis rate, tumor marker levels, T lymphocyte subsets, estrogen receptor levels, and progesterone receptor levels before and after were compared between the two groups. Results: The efficacy of the observation group was higher than that of the control group, and the recurrence and metastasis rates were (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Before treatment there were no significant differences in tumor marker levels, T lymphocyte subsets, estrogen receptor levels, and progesterone receptor levels between the two groups (P>.05). After treatment, the tumor marker levels in the observation group were lower than those in the control group, and the T lymphocyte subsets, estrogen levels, and progesterone receptor levels were higher (P<0.05). Conclusion: Trastuzumab combined with chemotherapy has a high efficacy patients with HER2 positive breast cancer.
References
[1] Liu Heng, Li Xiu-nan, Wang Gang-le. Efficacy of dual-targeting trastuzumab pertuzumab combined with chemotherapy drugs in
neoadjuvant treatment of human epidermal growth factor receptor 2-positive breast cancer and influencing factors [J ]China Medicine, 2023,
18(10): 1517-1521.
[2] Chen J D. Clinical study on the efficacy and safety of trastuzumab combined with nedaplatin in treating epidermal growth factor
receptor-2 positive breast cancer[J]. Capital Food & Medicine, 2023, 30(21): 52-54.
[3] Xia L, Ma W B. Efficacy of albumin paclitaxel combined with trastuzum and pertuzumab in patients with human epidermal growth
factor receptor 2 positive breast cancer[J]. Journal of North Sichuan Medical College, 023, 38(11): 1522-1525, 1567.
[4] Cui J W, Liu Y H, Liu X L, et al. Efficacy of dual-target combined chemotherapy drugs inoadjuvant treatment of HER2-positive
breast cancer and its influencing factors[J]. Chinese Journal of Clinical Physicians (Electronic Edition), 2022, 6(11): 1062-1067.
[5] Tang Y, Zhang Q, Tan D, et al. Efficacy of trastuzumab combined with pertuzum in treating HER2-positive breast cancer and its
effect on changes in serum miR-375 and miR-30d expression [J]. He Medical Journal, 2023, 29(11): 1916-1922.
[6] Wei Songzhi, Wei Shuqin, Li Bo. Efficacy and safety of neoadjuvant pertuzab in combination with trastuzumab in elderly patients
with locally advanced, inflammatory, or early HER2-positive breast cancer [J]. Chinese Journal of Ger, 2023, 43(1): 44-47.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
